Rosalind Advisors Inc. Invests $10.61 Million in Chimerix, Inc. (NASDAQ:CMRX)

Rosalind Advisors Inc. purchased a new stake in Chimerix, Inc. (NASDAQ:CMRX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 3,050,000 shares of the biopharmaceutical company’s stock, valued at approximately $10,614,000. Chimerix makes up 5.3% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 4th biggest holding. Rosalind Advisors Inc. owned approximately 3.39% of Chimerix at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the stock. Bender Robert & Associates purchased a new position in shares of Chimerix in the 4th quarter worth approximately $37,000. Stoneridge Investment Partners LLC lifted its holdings in shares of Chimerix by 22.5% during the fourth quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 8,134 shares during the period. Charles Schwab Investment Management Inc. acquired a new stake in Chimerix during the 4th quarter valued at approximately $183,000. Palumbo Wealth Management LLC purchased a new stake in Chimerix in the fourth quarter valued at $221,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Chimerix by 66.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 138,098 shares during the last quarter. Hedge funds and other institutional investors own 45.42% of the company’s stock.

Analysts Set New Price Targets

CMRX has been the topic of a number of analyst reports. Wedbush restated a “neutral” rating and set a $8.55 target price (up from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th. Jefferies Financial Group reissued a “hold” rating and issued a $8.50 price objective (down from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. HC Wainwright restated a “neutral” rating and set a $8.55 target price (down from $11.00) on shares of Chimerix in a report on Wednesday, March 5th. Finally, StockNews.com started coverage on Chimerix in a research note on Saturday, March 15th. They issued a “hold” rating for the company.

Chimerix Price Performance

NASDAQ CMRX opened at $8.50 on Friday. The stock has a market capitalization of $764.46 million, a P/E ratio of -9.04 and a beta of 0.32. The firm’s 50-day moving average is $5.34 and its two-hundred day moving average is $2.83. Chimerix, Inc. has a 12 month low of $0.75 and a 12 month high of $8.52.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. The company had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.31 million. As a group, analysts anticipate that Chimerix, Inc. will post -0.99 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Michael T. Andriole sold 7,370 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 20,760 shares of company stock worth $91,175 over the last ninety days. Corporate insiders own 13.10% of the company’s stock.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.